modithromycin
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2005 (NCT00270517)
Timeline
Indications
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
Loading structure…
SMILES
CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@@]2(C)C[C@@H](C)/C(=N\C(C)=O)[C@H](C)[C@@H](OC/C(=N\OCc3ccc(-n4cccn4)nc3)CO2)[C@]1(C)O- Mol. weight
- 841.02 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL263886 ↗
Also known as
- edp-322
- edp420
- edp 420
- edp-420
- edp-420
- edp-420
- ep-013420
- modithromycin
- s-013420
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00989872 | Phase 1 | Oct 5, 2009 | Enanta Pharmaceuticals, PPD |
| NCT00990145 | Phase 1 | Nov 1, 2008 | Enanta Pharmaceuticals |
| NCT00270517 | Phase 2 | Dec 1, 2005 | Enanta Pharmaceuticals |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Enanta Pharmaceuticals | For profit | 3 | 3 | 2 | 2005 |
| PPD | For profit | 1 | 0 | 1 | 2009 |
2 organizations
Page 1 / 1